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Summary
Background: Taurine (2-aminoethanesulfonic acid) is a semi-essential amino acid found in mam-
malian tissues that is not involved in protein synthesis. The function of taurine is not completely
understood. Some studies have demonstrated that taurine supplementation reduces death rate
in rabbits with heart failure (HF) and diminishes HF severity in human models of congestive HF.
In this study we have evaluated the effect of taurine supplementation on exercise capacity of
patients with HF.
Methods: A randomized single-blind placebo-controlled clinical trial was conducted on 29
patients with HF with left ventricular ejection fraction (LVEF) less than 50% who were in func-
tional class II or III according to New York Heart Association classiﬁcation. A total of 15 patients
received taurine supplementation 500mg three times a day while the remaining 14 patients
ks. All patients performed exercise tolerance test before and afterreceived placebo for 2 wee
taurine and placebo supplementation.
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Results: The mean age of patients was 60.57± 6.54 years, they were mostly male (26 of 29),
and had mean LVEF of 29.27± 6.97%. There were no signiﬁcant differences in terms of LVEF, body
mass index, and also exercise time, metabolic equivalents (METS) and exercise distance before
supplementation. Exercise time, METS, and exercise distance increased signiﬁcantly in patients
who received taurine supplement for 2 weeks (p-value < 0.0001 for all), but did not increase
signiﬁcantly in patients who received placebo (p-values 0.379, 0.244, and 0.577 respectively).
Conclusion: Taurine supplementation in patients with HF who are taking standard medical treat-
cise
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0.577) (Table 3).
Discussionment can increase their exer
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ackground
aurine (2-aminoethanesulfonic acid) is a semi-essential
mino acid found in mammalian tissues that is not involved
n protein synthesis and is the most abundant free amino
cid in the heart, retina, skeletal muscle, brain, and leuko-
ytes [1]. Taurine’s function is not understood completely
ut some cellular osmoregulations are modulated by taurine
2,3]. It has been demonstrated in vitro in various species
hat low levels of taurine are associated with various patho-
ogical lesions, including cardiomyopathy [4].
Taurine has been used in experimental and clinical stud-
es for treating several cardiovascular diseases including
ypertension, hypercholesterolemia, atherosclerosis, car-
iomyopathy, and congestive heart failure (CHF) [2,5—7].
In experimental CHF in dogs [8] and rabbits [9] increasing
aurine levels in heart have been shown, as in left ventricular
uscle of patients who had died of CHF [10].
Some studies have demonstrated that taurine supplemen-
ation reduces death rate in rabbits with heart failure (HF)
9] and diminishes HF severity in human models of CHF [11].
In this study we have evaluated the effect of taurine
upplementation on exercise capacity of patients with HF.
ethods
randomized single-blind placebo-controlled clinical trial
pproved by the ethics committee of Shahid Beheshti
edical University was executed in accordance with the Dec-
aration of Helsinki in Loghman Hakim Hospital in Tehran,
ran in 2008. After obtaining their informed consents, 29
atients with HF due to coronary heart disease with left
entricle ejection fraction (LVEF) less than 50% who were in
unctional class II or III according to New York Heart Associ-
tion (NYHA) classiﬁcation were randomized to four groups
Table 1): seven patients who received taurine supplementa-
ion (Taurine capsule, Solgar, Leonia, NJ, USA) 500mg three
imes a day for 2 weeks and performed exercise tolerance
est (ETT) with Bruce protocol before and after taurine
upplementation; eight patients received taurine and per-
ormed ETT with modiﬁed Bruce protocol; and six and eight
atients received placebo (starch) and performed ETT with
ruce and modiﬁed Bruce protocols, respectively.
NDrug history, electrocardiogram characteristics, heart
ates (HR) and blood pressures (BP) of patients were
ecorded before ETT and then a 10-mL blood sample was
aken for measuring taurine serum levels by high perfor-
ance liquid chromatography (HPLC) method. In addition to
he usual parameters of ETT, metabolic equivalents (METS)
nd distances patients had covered were recorded. After
T
t
wcapacity.
ology. Published by Elsevier Ltd. All rights reserved.
weeks of supplementation, all of these parameters were
easured again. We used chi-square tests (Fisher’s exact
est where applicable) for categorical variables and ANOVA
nd Tukey’s tests for quantitative variables to analyze our
ata. A p-value less than 0.05 was considered statistically
igniﬁcant. SPSS 13.0 for Windows (SPSS, Inc., Chicago, IL,
SA) was used for all statistical tests.
esults
he patients had a mean age of 60.57± 6.54 (50—65
ears) years, were mostly male (26 of 29) and had mean
VEF of 29.27± 6.97%. There were no signiﬁcant dif-
erences in terms of LVEF, body mass index (BMI) and
lso exercise time, METS and exercise distance before
upplementation (Table 2). Drug history regarding use
f angiotensin-converting enzyme inhibitors, angiotensin
eceptor blockers, beta blockers, aspirin, statins, diuretics,
nd nitrates before and after supplementation was not
igniﬁcantly different between groups with taurine supple-
ent and placebo supplement (p-values were 0.876, 0.483,
.33 0.483, 0.10, 0.191, and 1, respectively).
Exercise time, METS, and exercise distance in group 1
taurine — Bruce) increased signiﬁcantly (p-values were
.022, 0.043, and 0.012, respectively).
In group 2 (taurine — modiﬁed Bruce) also, exercise time,
ETS, and exercise distance increased signiﬁcantly (p-values
ere 0.000, 0.001, and 0.003, respectively).
Exercise time, METS, and exercise distance were
ncreased signiﬁcantly in all of 15 patients who received
aurine supplement (group 1 + group 2) after 2 weeks (p-
alues < 0.0001 for all).
In group 3 (placebo — Bruce), exercise time, METS, and
xercise distance did not increase signiﬁcantly (p-values
ere 0.264, 0.057, and 0.099, respectively).
Exercise time and exercise distance did not increase sig-
iﬁcantly (p-values were 0.155 and 0.071, respectively) in
roup 4 (placebo — modiﬁed Bruce), but METS increased
igniﬁcantly (p-value = 0.029).
All of these parameters did not increase signiﬁcantly in
ll of 14 patients (group 3 + group 4) who did not receive
aurine supplementation (p-values were 0.379, 0.244, andhis study shows that taurine supplementation 500mg three
imes a day in patients with HF in NYHA class II or III, who
ere on medical treatment, increased exercise time, METS,
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Table 1 Patient randomization groups.
ETT protocol Taurine supplement Placebo Total
N Group name N Group name
Bruce 7 Taurine — Bruce (G1) 6 Placebo — Bruce (G3) 13
Modiﬁed Bruce 8 Taurine — M Bruce (G2) 8 Placebo — M Bruce (G4) 16
Total 15 14 29
ETT, exercise tolerance test.
Table 2 Patients’ characteristics before taurine supplementation according to comparison of various groups.
Group G1 G3 p-value G2 G4 p-value G1 +G2 G3 +G4 p-value
Deﬁnition T-B P-B T-MB P-MB T-B +MB P-B +MB
n 7 6 — 8 8 — 15 14 —
Sex (M) 6 5 — 8 7 — 14 12 —
Age mean (years) 61.7 ± 6.4 60.4 ± 6.95 0.78 60.13 ± 5.36 61.13 ± 8.36 0.13 60.87 ± 5.72 60.26 ± 7.45 0.8
BMI (kg/m2) 25.2 ± 3.4 22.9 ± 1.20 0.21 24.22 ± 1.05 24.23 ± 1.10 0.93 24.65 ± 2.43 23.65 ± 1.2 0.35
EF (%) 27.8 ± 8.1 31.4 ± 8.1 0.72 29.75 ± 4.97 28.13 ± 7.53 0.59 28.68 ± 6.43 29.66 ± 7.66 0.83
BP1 sys (mmHg) 121.4 ± 16 115.71 ± 11.34 0.36 106.25 ± 10.61 108.75 ± 15.53 0.53 113.33 ± 15.43 112.14 ± 14.23 0.45
BP1 dias (mmHg) 75.7 ± 12.7 68.57 ± 6.90 0.05 66.25 ± 7.44 65.00 ± 9.26 0.54 70.67 ± 10.99 66.43 ± 8.42 0.33
HR rest 1 (/min) 70.29 ± 9.29 70.86 ± 7.75 0.9 69.38 ± 11.76 68.25 ± 10.42 0.84 69.80 ± 10.31 69.47 ± 9.05 0.92
HR max 1 (/min) 124.7 ± 9.5 134.5 ± 32.66 0.83 117.50 ± 22.904 120.0 ± 22.297 0.76 120.87 ± 17.74 126.21 ± 27.08 0.01
Serum taurine 1 (mol/l) 55.8 ± 19.1 49.0 ± 6.97 0.01 58.875 ± 19.63 44.125 ± 9.19 0.82 57.47 ± 18.7 46.21 ± 8.13 0.00
Ex time 1 (Min) 5.3 ± 2.1 5.485 ± 2.70 0.24 9.2075 ± 2.52 6.92 ± 2.06 0.55 7.32 ± 3.09 6.307 ± 2.37 0.15
METS1 4.991 ± 0.90 5.216 ± 1.13 0.34 7.525 ± 1.82 5.975 ± 1.62 0.51 6.342 ± 1.93 5.650 ± 1.43 0.10
Distance 1 (m) 458.57 ± 209.27 488.166 ± 231.72 0.64 729.0 ± 178.24 516.5 ± 198.93 0.75 602.8 ± 232.71 504.357 ± 205.36 0.9
T, taurine; B, Bruce protocol; P, placebo; MB, modiﬁed Bruce protocol; BMI, body mass index; EF, ejection fraction; BP blood pressure; sys, systolic; dias, diastolic; HR, heart rate; Ex,
exercise; METS, metabolic equivalents; 1 = before supplementation.
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Table 3 Patients’ data before and after taurine supplementation.
Group G1 G2 G1 +G2 G3 G4 G3 +G4
Deﬁnition T-B T-MB T-B +MB P-B P-MB P-B +MB
n 7 8 15 6 8 14
Sex (M) 6 8 14 5 7 12
Age mean (years) 6.4 ± 61.7 60.13 ± 5.36 60.87 ± 5.72 60.4 ± 6.95 61.13 ± 8.36 60.26 ± 7.45
BMI (kg/m2) 25.2 ± 3.4 24.22 ± 1.05 24.65 ± 2.43 22.9 ± 1.20 24.23 ± 1.10 23.65 ± 1.2
EF (%) 27.8 ± 8.1 29.75 ± 4.97 28.68 ± 6.43 31.4 ± 8.1 28.13 ± 7.53 29.66 ± 7.66
BP1 rest sys (mmHg) 16 ± 121.4 106.25 ± 10.61 113.33 ± 15.43 115.71 ± 11.34 108.75 ± 15.53 112.14 ± 14.23
BP2 rest systole (mmHg) 107.14 ± 12.54 106.25 ± 9.16 106.67 ± 10.47 123.33 ± 10.3 112.5 ± 8.87 117.14 ± 10.69
p-value 0.08 1.00 0.126 0.286 0.504 0.205
BP1 rest diastole (mmHg) 12.7 ± 75.7 66.25 ± 7.44 70.67 ± 10.99 68.57 ± 6.90 65.00 ± 9.26 66.43 ± 8.42
BP2 rest diastole (mmHg) 68.57 ± 6.90 68.75 ± 8.34 68.67 ± 7.43 76.67 ± 10.32 70.0 ± 5.34 72.86 ± 8.25
p-value 0.182 0.351 0.486 0.042 0.104 0.007
HR max 1 (/min) 124.7 ± 9.5 117.50 ± 22.90 120.87 ± 17.74 134.5 ± 32.66 120.0 ± 22.29 126.21 ± 27.08
HR max 2 (/min) 7.2 ± 125.8 118.13 ± 11.91 121.73 ± 10.45 128.0 ± 27.39 125.75 ± 14.95 126.71 ± 20.25
p-value 0.419 0.932 0.818 0.620 0.488 0.943
Serum taurine level 1 (mol/l) 55.8 ± 19.1 58.875 ± 19.63 57.47 ± 18.74 49.0 ± 6.97 44.125 ± 9.19 46.21 ± 8.13
Serum taurine level 2 (mol/l) 29.4 ± 136 140.50 ± 30.12 138.40 ± 28.84 65.83 ± 14.61 61.63 ± 30.29 63.43 ± 24.10
p-value 0.001 0.000 0.000 0.052 0.200 0.036
Ex time 1 (min) 2.1 ± 5.3 9.21 ± 2.52 7.32 ± 3.09 5.48 ± 2.70 6.92 ± 2.06 6.31 ± 2.37
Ex time 2 (min) 2.8 ± 8.7 12.39 ± 2.66 10.09 ± 3.74 4.83 ± 2.30 8.44 ± 3.64 6.89 ± 3.55
p-value 0.022 0.000 0.000 0.264 0.154 0.379
METS 1 4.99 ± 0.90 7.52 ± 1.82 6.34 ± 1.93 5.22 ± 1.13 5.97 ± 1.62 5.65 ± 1.43
METS 2 6.04 ± 1.45 9.75 ± 2.06 8.02 ± 2.58 4.67 ± 1.17 7.11 ± 2.49 6.06 ± 2.33
p-value 0.043 0.001 0.000 0.057 0.029 0.244
Distance 1 (m) 458.57 ± 209.27 729.0 ± 178.24 602.8 ± 232.71 488.166 ± 231.72 516.5 ± 198.93 504.357 ± 205.36
Distance 2 (m) 648.57 ± 278.22 941.125 ± 209.20 804.60 ± 279.07 417.666 ± 191.01 603.87 ± 198.93 524.071 ± 243.67
p-value 0.012 0.003 0.000 0.099 0.071 0.577
T, taurine; B, Bruce protocol; P, placebo; MB, modiﬁed Bruce protocol; BMI, body mass index; EF, ejection fraction; BP blood pressure; sys, systolic; dias, diastolic; HR, heart rate; Ex,
exercise; METS, metabolic equivalents; 1 = before supplementation; 2 = after supplementation.
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and exercise distance. Animal studies demonstrate that tau-
rine supplementation prevents or slows HF development,
reduces mortality, and hence improves survival [12—14].
However, in humans, there is paucity of data on assess-
ment of taurine effects on HF. Azuma et al. showed that
taurine supplementation with a dose of 2 g BID for 4 or 8
weeks in 24 patients with CHF improved their clinical sit-
uations and NYHA functional class [11]. In a double-blind
crossover trial on 14 patients with CHF, Azuma et al. demon-
strated that taurine supplementation for a 4-week period
improved NYHA functional class, pulmonary crackles, and
chest ﬁlm abnormalities in comparison with placebo [15].
In another study Azuma et al. evaluated the effect of
oral administration of taurine (3 g/day) and coenzyme Q10
(CoQ10) (30mg/day) in 17 patients with CHF secondary to
ischemic or idiopathic dilated cardiomyopathy with LVEF less
than 50% and showed signiﬁcant improvement in LV systolic
function after 6 weeks [16].
The positive effects of taurine on LV function may be due
to its regulatory role in intracellular Ca2+ homeostasis via its
effect on voltage-dependent Ca2+ channels, by regulation of
Na+ channels, and via Na—Ca exchange and Na(+)-taurine
cotransport [17,18]. Hence taurine modulates intracellu-
lar Ca2+ levels. Taurine also has a potent antioxidant role
that may contribute to its potential beneﬁts in patients
with HF [19]. The failing myocardium exhibits increased
intracellular and mitochondrial calcium, which results in a
decrease in myocardial energy production and an increase
in oxidative stress [20]. Taurine has many other effects on
the cardiovascular system including its beneﬁcial impact on
macrovascular endothelial function [21] that may have some
speculative role in patients with HF.
To the best of our knowledge, our study is the ﬁrst clinical
trial that speciﬁcally assesses the effect of taurine supple-
mentation on exercise capacity of patients with HF and is
compatible with other studies that have shown a positive
effect of taurine on patients with HF.
Limitations of this study include small size of the sample,
single-blind study and lack of repetition of echocardiography
after supplementation.
Conclusion
Taurine supplementation in patients with CHF who are tak-
ing standard medical treatment can increase their exercise
capacity.
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